The Impact of B3GNT7 on Properties of Intestinal Mucus and the Gut Microbiome

B3GNT7 对肠粘液和肠道微生物组特性的影响

基本信息

项目摘要

Project Summary The human intestine is colonized by a diverse array of almost 100 trillion bacteria that are critical for health. Intestinal mucus is the critical interface between the host and the gut microbiome; it is a barrier between humans and pathogenic microbes, and it is also an attractant for beneficial microbes, supporting vital commensal microbes with nutrients and attachment sites. The main components of intestinal mucus are highly O-glycosylated mucins and other glycoproteins. Inflammatory bowel diseases, such as ulcerative colitis and Crohn’s, are characterized by gut inflammation that results in dysbiosis of the microbiome and alterations in intestinal mucus glycan structures. The molecular structure of mucus has functional significance. Fucosylation is abundant in mammalian intestinal mucus, and it has been shown to regulate commensal microbe colonization and maintain host-microbe symbiosis. Additionally, fucosylation has been shown to alter the quality and quantity of intestinal mucus in ulcerative colitis patients. Mucin sulfation has also been implicated in ulcerative colitis. β1-3-N-acetylglucosaminyltransferase 7 (B3GNT7) is an O-glycosyltransferase present on the Golgi apparatus membrane that transfers GlcNAc to glycan substrates and participates in polyLacNAc chain biosynthesis. Importantly, these polyLacNAc chains can go on to be further modified by fucose and/or sulfate. We previously reported that that IL-22, a cytokine critical for maintaining intestinal epithelial homeostasis, promotes B3GNT7 expression, increases fucosylated O-glycans, and increases polyLacNAc chains on a model of the human intestinal epithelium. Furthermore, we found that overexpression of B3GNT7 is sufficient to increase cell surface fucosylation. The research outlined in this proposal that B3GNT7 functions to maintain healthy intestinal mucus and support beneficial commensal gut microbes. This proposal will 1) Define the impact of B3GNT7 on the biophysical properties of intestinal mucus in cell lines and mice; and 2) Determine the effect of B3gnt7 expression on host-microbiome interactions. Regulation of intestinal mucus and the microbiome is poorly understood, and the experiments outline above will elucidate how changes in glycosylation regulate the microbiome at the molecular and tissue level. Importantly, it will lay the foundation for future studies of how glycosylation of intestinal mucus contributes to both human health and disease.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

相似国自然基金

32P-可降解微球调控TAM-FABP1细胞群的脂质代谢对肝细胞癌免疫微环境的影响及机制
  • 批准号:
    82372065
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
冷泉硫酸盐还原菌碳硫代谢影响微生物群落演替的作用机制
  • 批准号:
    42306171
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
儿童脂肪、肌肉构成及相互作用对心血管代谢异常发生风险的影响及机制研究
  • 批准号:
    82373589
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
DJ-1通过影响UCP1稳定性调控机体代谢稳态的机制研究
  • 批准号:
    32371194
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
桑叶多糖与肠道菌群互作产物通过影响肝miRNA调控脂代谢的作用机制研究
  • 批准号:
    32372245
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目

相似海外基金

Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
  • 批准号:
    10752555
    10752555
  • 财政年份:
    2024
  • 资助金额:
    $ 3.86万
    $ 3.86万
  • 项目类别:
Maternal immune activation remodeling of offspring glycosaminoglycan sulfation patterns during neurodevelopment
神经发育过程中后代糖胺聚糖硫酸化模式的母体免疫激活重塑
  • 批准号:
    10508305
    10508305
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
    $ 3.86万
  • 项目类别:
Center of Research Translation on Osteoporosis Bone Anabolic Therapies
骨质疏松症骨合成代谢疗法研究转化中心
  • 批准号:
    10404412
    10404412
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
    $ 3.86万
  • 项目类别:
Regulation of CSE-Derived Hydrogen Sulfide in the Heart
CSE 衍生的硫化氢在心脏中的调节
  • 批准号:
    10659832
    10659832
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
    $ 3.86万
  • 项目类别:
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
    $ 3.86万
  • 项目类别: